Sign in Subscribe
Medical centers

Long-term Outcomes of Tricuspid Valve Procedures with Continuous-Flow Left Ventricular Assist Devices

Strategic Insights

— 1 min read

Investigators from Columbia University Irving Medical Center published a new report on the outcomes of concomitant tricuspid valve procedures with continuous-flow left ventricular assist devices (LVADs). The retrospective study reviewed patients who received a HeartMate II or 3 LVAD between 2004 and 2023, focusing on the long-term outcomes of concomitant tricuspid valve procedures during LVAD implantation. The research found that concomitant tricuspid valve procedures with LVAD implantation were associated with reduced mortality and reduced grade of tricuspid regurgitation over an 8-year follow-up period.

Key Takeaways:

  • The study retrospectively reviewed 727 patients who received a HeartMate II or 3 LVAD between 2004 and 2023, with 102 (14.0%) patients undergoing a concomitant tricuspid valve procedure (TVP).
  • The TVP group had a lower risk of mortality compared to the No TVP group after the first year of surgery (adjusted hazard ratio, 0.227; 95% confidence interval, 0.082-0.633; P = 0.02).
  • Concomitant TVP with LVAD implantation was associated with reduced grade of tricuspid regurgitation over an 8-year follow-up period.
  • The study found no significant difference in readmissions between the TVP and No TVP groups.
  • The median age of the matched cohorts was 59.0 years (interquartile range, 49.2-67.0 years), with 144 males (80.0%) and 172 patients (95.6%) receiving LVAD as destination therapy.

Statistics:

  • 727 patients were reviewed in the study, with 102 (14.0%) undergoing a TVP.
  • The study found a lower risk of mortality in the TVP group after the first year of surgery (adjusted hazard ratio, 0.227; 95% confidence interval, 0.082-0.633; P = 0.02).
  • 90 patients were matched in each cohort (TVP and No TVP) using propensity score matching (PSM).
  • 59.0 years was the median age of the matched cohorts, with an interquartile range of 49.2-67.0 years.
  • 144 males (80.0%) and 172 patients (95.6%) received LVAD as destination therapy.

Sources:

  • Long-term outcomes of tricuspid valve repair or replacement in patients with a continuous-flow left ventricular assist device. The Journal of Thoracic and Cardiovascular Surgery, 2025.
  • NewsRx. Studies from Columbia University Irving Medical Center Update Current Data on Left Ventricular Assist Device (Long-term outcomes of tricuspid valve repair or replacement in patients with a continuous-flow left ventricular assist device). Medical Devices & Surgical Technology Week. October 26, 2025; p 2031.

Read more